CN104817507A - 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法 - Google Patents

用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法 Download PDF

Info

Publication number
CN104817507A
CN104817507A CN201510116934.6A CN201510116934A CN104817507A CN 104817507 A CN104817507 A CN 104817507A CN 201510116934 A CN201510116934 A CN 201510116934A CN 104817507 A CN104817507 A CN 104817507A
Authority
CN
China
Prior art keywords
amino
polymorph
triazole
orotate
cto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510116934.6A
Other languages
English (en)
Chinese (zh)
Inventor
R.A.卡玛丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KARMALI RASHIDA Co
Original Assignee
KARMALI RASHIDA Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43648255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104817507(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KARMALI RASHIDA Co filed Critical KARMALI RASHIDA Co
Publication of CN104817507A publication Critical patent/CN104817507A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201510116934.6A 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法 Pending CN104817507A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58444809A 2009-09-04 2009-09-04
US12/584,448 2009-09-04
CN201080050000.2A CN102595904B (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法
US12/807,415 US8377973B2 (en) 2009-09-04 2010-09-03 Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
US12/807,415 2010-09-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201080050000.2A Division CN102595904B (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法

Publications (1)

Publication Number Publication Date
CN104817507A true CN104817507A (zh) 2015-08-05

Family

ID=43648255

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510116934.6A Pending CN104817507A (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法
CN201080050000.2A Active CN102595904B (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201080050000.2A Active CN102595904B (zh) 2009-09-04 2010-09-03 用于制备5-氨基或取代的氨基1,2,3-三唑和三唑乳清酸盐制剂的新组合物和方法

Country Status (19)

Country Link
US (1) US8377973B2 (https=)
EP (2) EP2473051B1 (https=)
JP (4) JP2013503861A (https=)
KR (1) KR101597338B1 (https=)
CN (2) CN104817507A (https=)
AP (1) AP3345A (https=)
AU (1) AU2010290049B2 (https=)
BR (1) BR112012004539A2 (https=)
CA (1) CA2772075C (https=)
CL (1) CL2012000582A1 (https=)
HK (1) HK1212983A1 (https=)
IL (1) IL218430A0 (https=)
MX (2) MX2012002730A (https=)
MY (1) MY159430A (https=)
NZ (2) NZ598482A (https=)
PH (1) PH12015502088A1 (https=)
RU (1) RU2594155C2 (https=)
SG (1) SG178413A1 (https=)
WO (1) WO2011028288A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112083109A (zh) * 2019-07-08 2020-12-15 广东银珠医药科技有限公司 羧胺三唑杂质及其制备方法和检测方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
US9089570B2 (en) * 2010-09-03 2015-07-28 Tactical Therapeutics Inc Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
US10378059B2 (en) * 2013-08-02 2019-08-13 Tactical Therapeutics, Inc. Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
KR102623581B1 (ko) * 2016-07-18 2024-01-11 일동제약(주) 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate
CN112358451B (zh) * 2021-01-11 2021-04-13 广东银珠医药科技有限公司 羧胺三唑的合成方法
CN113582935A (zh) * 2021-08-27 2021-11-02 中国医学科学院放射医学研究所 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用
CN113620892B (zh) * 2021-10-12 2022-02-22 广东银珠医药科技有限公司 羧胺三唑单晶、制备方法及其组合物和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590201A (en) * 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
EP0304221A2 (en) * 1987-08-20 1989-02-22 Merck & Co. Inc. 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents
CN101273988A (zh) * 1995-07-21 2008-10-01 巧妙疗法股份有限公司 用氨基咪唑甲酰胺和5-氨基或取代的氨基1,2,3-三唑的盐治疗和预防肿瘤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2415740C2 (de) 1974-04-01 1983-12-01 Servomed Arznei GmbH & Co Pharma KG, 8000 München Verwendung von Orotsäure bei der analgetischen Behandlung mit Dextropropoxyphen, Natriumsalicylat oder Metamizol
JPH0356417A (ja) * 1989-05-08 1991-03-12 Merck & Co Inc 抗転移剤として有用な５―アミノ又は置換アミノ１，２，３―トリアゾール類
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
CA2575902C (en) 1995-07-21 2010-06-08 Tactical Therapeutics Inc Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
WO2005116024A1 (en) * 2004-05-25 2005-12-08 Astrazeneca Ab 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
KR20100059919A (ko) * 2007-09-24 2010-06-04 코멘티스, 인코포레이티드 치료를 위한 베타-세크레타제 억제제로서 (3-히드록시-4-아미노-부탄-2일)-3-(2-티아졸-2-일-피롤리딘-1-카르보닐) 벤즈아미드 유도체 및 관련 화합물
US20150323994A1 (en) * 2014-05-07 2015-11-12 Immersion Corporation Dynamic haptic effect modification
JP2017150532A (ja) * 2016-02-23 2017-08-31 Ntn株式会社 回転伝達装置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590201A (en) * 1984-02-02 1986-05-20 Merck & Co., Inc. 5-amino or substituted amino 1,2,3-triazoles
EP0304221A2 (en) * 1987-08-20 1989-02-22 Merck & Co. Inc. 5-amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents
CN101273988A (zh) * 1995-07-21 2008-10-01 巧妙疗法股份有限公司 用氨基咪唑甲酰胺和5-氨基或取代的氨基1,2,3-三唑的盐治疗和预防肿瘤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREW S. THOMPSON，等: "Direct Conversion of Activated Alcohols to Azides Using Diphenyl Phosphorazidate. A Practical Alternative to Mitsunobu Conditions", 《J. ORG. CHEM.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112083109A (zh) * 2019-07-08 2020-12-15 广东银珠医药科技有限公司 羧胺三唑杂质及其制备方法和检测方法

Also Published As

Publication number Publication date
AU2010290049A1 (en) 2012-03-29
EP2473051A4 (en) 2013-03-13
EP2473051A1 (en) 2012-07-11
IL218430A0 (en) 2012-04-30
EP2473051B1 (en) 2016-02-10
NZ598482A (en) 2014-05-30
WO2011028288A1 (en) 2011-03-10
AP2012006187A0 (en) 2012-04-30
JP2020105178A (ja) 2020-07-09
CN102595904A (zh) 2012-07-18
JP2013503861A (ja) 2013-02-04
AU2010290049B2 (en) 2013-09-19
CA2772075C (en) 2017-02-28
EP2963023A1 (en) 2016-01-06
CA2772075A1 (en) 2011-03-10
JP2017203038A (ja) 2017-11-16
HK1212983A1 (zh) 2016-06-24
CL2012000582A1 (es) 2012-09-07
SG178413A1 (en) 2012-03-29
PH12015502088B1 (en) 2017-03-22
RU2012111454A (ru) 2013-10-10
RU2594155C2 (ru) 2016-08-10
MY159430A (en) 2017-01-13
MX2012002730A (es) 2012-07-20
KR20120092587A (ko) 2012-08-21
US8377973B2 (en) 2013-02-19
BR112012004539A2 (pt) 2020-09-15
JP2016026213A (ja) 2016-02-12
MX355198B (es) 2018-04-06
US20110060142A1 (en) 2011-03-10
PH12015502088A1 (en) 2017-03-22
CN102595904B (zh) 2016-08-03
EP2963023B1 (en) 2018-04-18
AP3345A (en) 2015-07-31
KR101597338B1 (ko) 2016-02-24
NZ624636A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
HK1212983A1 (zh) 用於制备5-氨基或取代的氨基1，2，3-三唑和三唑乳清酸盐制剂的新组合物和方法
CN100471840C (zh) 制备罗氟司特的方法
EP2041068B1 (en) Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
CN104016951B (zh) 靶向癌症干细胞的化合物和组合物
CN103002890A (zh) 靶向癌症干细胞的新的化合物和组合物
US20140142147A1 (en) Carbocyanines for G-Quadruplex DNA Stabilization and Telomerase Inhibition
US20240382511A1 (en) Nicotinamide mononucleotide derivatives and use thereof for the treatment of heart failure with preserved ejection fraction
US8912223B2 (en) Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations
Zhang et al. Dissolution and pharmacokinetic properties of two paliperidone cocrystals with 4-hydroxybenzoic and 4-aminobenzoic acid
HK1170631A (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
CN115702902A (zh) 一种阿霉素前药抗肿瘤制剂
HK1170631B (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
HK1214824A1 (en) Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives
HK1214824B (en) Process for preparing 5-amino-1, 2, 3-triazole orotate derivatives
WO2022087763A1 (zh) 含有索拉非尼游离碱和5-氟尿嘧啶的共晶体、药物组合物及其用途
EP4003354A1 (en) Cocrystals of posaconazole, methods of making and using same
EP2991682B1 (en) Prodrugs of naproxen and diclofenac
CN103772374B (zh) 一种杂环类化合物及其应用
HK1239527A1 (en) Novel compounds and compositions for targeting cancer stem cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212983

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150805